Revance’s board urges stockholders to vote in favor of Crown’s acquisition offer
Revance (RVNC) and Crown Laboratories reminded Revance stockholders of the recommendation to tender their shares in support of Crown’s cash ...
Revance Therapeutics set to go private with Crown Laboratories
Johnson City-based Crown Laboratories is now offering the public biotechnology company’s stockholders $3.65 per share of its ...
Revance Therapeutics soars after Crown Labs raises offer to $3.65 a share
Revance Therapeutics (NASDAQ:RVNC) jumped 11% in premarket trading after Crown Laboratories increased its offer above Teoxane's latest bid. Crown Labs increased its offer to $3.65 a share, above ...
Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer
Crown Laboratories Tuesday increased its offer price to acquire Revance Therapeutics (NASDAQ:RVNC) to $3.65 per share, a $0.55 per share increase. Improved offer unanimously approved by Revance ...
Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced ...
The Bakersfield Californian11d
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance”), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated ...
Crown Labs Proposed Higher Revance Bid to Save Deal
Crown Laboratories plans to raise its takeover price for Revance Therapeutics to $3.65 a share, topping a rival $3.60-a-share bid from Swiss medical-aesthetics company Teoxane.